BeiGene (ONC) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending approval of Tevimbra, in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with recurrent, not amenable to curative surgery or radiotherapy, or metastatic NPC.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeiGene: Strong Sales and Promising Pipeline Drive Buy Rating
- BeiGene Holds Annual Shareholders Meeting, Key Resolutions Passed
- BeiGene price target raised to $350 from $348 at Guggenheim
- BeiGene’s Strong Market Position and Promising Financial Outlook Drive Buy Rating
- BeiGene Reports Strong Q1 2025 Growth and Profitability